Pfizer Opts Not to Split, Putting Focus on M&A and New DrugsBy and
‘More transactions seem likely,’ Bernstein analyst says
Drugmaker had signaled recently it may stay together
Pfizer Inc. decided not to split in two separate companies, opting against what could have been one of the biggest breakups in the drug industry’s history after years of what it called an “extensive evaluation.”
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.